Osteosarcoma

Oncology of Infancy and Childhood: Expert Consult - Online and Print

Volumn , Issue , 2009, Pages 871-910

  Janeway, Katherine A ^a,b   Gorlick, Richard ^c,d,e   Bernstein, Mark L ^f,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Department of Pediatrics ^*  (United States)

^e CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^f DALHOUSIE UNIVERSITY   (Canada)

^g IWK HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953408660     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3431-5.00022-4     Document Type: Chapter

References (391)

1. A Bleyer, M O'Leary, R Barr and LAG Ries (Eds) (2006) Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000 Bethesda, Md: National Cancer Institute (NIH Publication No. 06-5767)
2. L Peltier (1993) Tumors of bone and soft tissues. L Peltier,(Ed.) Orthopedics: A History and Iconography Novato, Calif: Norman Publishing 264-292
3. DC Dahlin and KK Unni (1977) Osteosarcoma of bone and its important recognizable varieties. Am J Surg Pathol 1 61-72
4. L Kager, A Zoubek, U Potschger, et al. (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21 2011-2018
5. PA Meyers, CL Schwartz, MD Krailo, et al. (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children's Oncology Group. J Clin Oncol 26 633-638
6. S Ferrari, A Briccoli, M Mercuri, et al. (2003) Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 21 710-715
7. B Kempf-Bielack, SS Bielack, H Jurgens, et al. (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23 559-568
8. DM Parkin, CA Stiller, GJ Draper and CA Bieber (1988) The international incidence of childhood cancer. Int J Cancer 42 511-520
9. CA Stiller (2007) International patterns of cancer incidence in adolescents. Cancer Treat Rev 33 631-645
10. LAG Ries, MA Smith, JG Gurney, et al. (Eds) (1999) Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute SEER Program (NIH Publication No. 99-4649)
11. SE Larsson and R Lorentzon (1974) The incidence of malignant primary bone tumours in relation to age, sex and site. A study of osteogenic sarcoma, chondrosarcoma and Ewing's sarcoma diagnosed in Sweden from 1958 to 1968. J Bone Joint Surg Br 56 534-540
12. CH Price (1955) Osteogenic sarcoma; an analysis of the age and sex incidence. Br J Cancer 9 558-574
13. RJ Grimer, SR Cannon, AM Taminiau, et al. (2003) Osteosarcoma over the age of forty. Eur J Cancer 39 157-163
14. S Kramer, AT Meadows, P Jarrett and AE Evans (1983) Incidence of childhood cancer: experience of a decade in a population-based registry. J Natl Cancer Inst 70 49-55
15. AP Polednak (1985) Primary bone cancer incidence in black and white residents of New York State. Cancer 55 2883-2888
16. HL Howe, X Wu, LA Ries, et al. (2006) Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 107 1711-1742
17. JD Buckley, TW Pendergrass, CM Buckley, et al. (1998) Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group. Cancer 83 1440-1448
18. EA Operskalski, S Preston-Martin, BE Henderson and BR Visscher (1987) A case-control study of osteosarcoma in young persons. Am J Epidemiol 126 118-126
19. LA Brostrom, U Adamson, R Filipsson and K Hall (1980) Longitudinal growth and dental development in osteosarcoma patients. Acta Orthop Scand 51 755-759
20. JF Fraumeni Jr (1967) Stature and malignant tumors of bone in childhood and adolescence. Cancer 20 967-973
21. A Longhi, A Pasini, A Cicognani, et al. (2005) Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol 27 314-318
22. KH Gelberg, EF Fitzgerald, S Hwang and R Dubrow (1997) Growth and development and other risk factors for osteosarcoma in children and young adults. Int J Epidemiol 26 272-278
23. MM Hawkins, LM Wilson, HS Burton, et al. (1996) Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88 270-278
24. WA Newton Jr, AT Meadows, H Shimada, et al. (1991) Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer 67 193-201
25. VB Le, VF de, A Shamsaldin, et al. (1998) Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 77 370-377
26. JF Kuttesch Jr, LH Wexler, RB Marcus, et al. (1996) Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 14 2818-2825
27. M Koshy, AC Paulino, WY Mai and BS Teh (2005) Radiation-induced osteosarcomas in the pediatric population. Int J Radiat Oncol Biol Phys 63 1169-1174
28. DA Pierce and DL Preston (2000) Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat Res 154 178-186
29. D Brenner, C Elliston, E Hall and W Berdon (2001) Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 176 289-296
30. FL Wong, JD Boice Jr, DH Abramson, et al. (1997) Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278 1262-1267
31. MF Hansen, A Koufos, BL Gallie, et al. (1985) Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A 82 6216-6220
32. B Wadayama, J Toguchida, T Shimizu, et al. (1994) Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54 3042-3048
33. FP Li, JF Fraumeni Jr, JJ Mulvihill, et al. (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48 5358-5362
34. M Overholtzer, PH Rao, R Favis, et al. (2003) The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 100 11547-11552
35. LL Wang, A Gannavarapu, CA Kozinetz, et al. (2003) Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst 95 669-674
36. MJ Hicks, JR Roth, CA Kozinetz and LL Wang (2007) Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome. J Clin Oncol 25 370-375
37. J German (1997) Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 93 100-106
38. M Goto, RW Miller, Y Ishikawa and H Sugano (1996) Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5 239-246
39. MP Whyte (2006) Clinical practice. Paget's disease of bone. N Engl J Med 355 593-600
40. RE Rowland, AF Stehney and HF Lucas Jr (1978) Dose-response relationships for female radium dial workers. Radiat Res 76 368-383
41. MM Finkelstein and N Kreiger (1996) Radium in drinking water and risk of bone cancer in Ontario youths: a second study and combined analysis. Occup Environ Med 53 305-311
42. MM Finkelstein (1994) Radium in drinking water and the risk of death from bone cancer among Ontario youths. CMAJ 151 565-571
43. CE Guse, AM Marbella, V George and PM Layde (2002) Radium in Wisconsin drinking water: an analysis of osteosarcoma risk. Arch Environ Health 57 294-303
44. H Vainio and P Kleihues (1994) IARC Working Group on Carcinogenicity of Beryllium. J Occup Med 36 1068-1070
45. ZS Rosenberg, S Lev, S Schmahmann, et al. (1995) Osteosarcoma: subtle, rare, and misleading plain film features. AJR Am J Roentgenol 165 1209-1214
46. B Widhe and T Widhe (2000) Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 82 667-674
47. SS Bielack, B Kempf-Bielack, G Delling, et al. (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20 776-790
48. G Bacci, A Longhi, M Versari, et al. (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106 1154-1161
49. M Gross and K Stevens (2005) Sunburst periosteal reaction in osteogenic sarcoma. Pediatr Radiol 35 647-648
50. T Gillespy III, M Manfrini, P Ruggieri, et al. (1988) Staging of intraosseous extent of osteosarcoma: correlation of preoperative CT and MR imaging with pathologic macroslides. Radiology 167 765-767
51. JL Bloem, AH Taminiau, F Eulderink, et al. (1988) Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. Radiology 169 805-810
52. DM Panicek, C Gatsonis, DI Rosenthal, et al. (1997) CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology 202 237-246
53. G Pan, AK Raymond, CH Carrasco, et al. (1990) Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology 174 517-526
54. WF Enneking and A Kagan (1975) “Skip” metastases in osteosarcoma. Cancer 36 2192-2205
55. L Kager, A Zoubek, U Kastner, et al. (2006) Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 24 1535-1541
56. FS Chew and TM Hudson (1982) Radionuclide bone scanning of osteosarcoma: falsely extended uptake patterns. AJR Am J Roentgenol 139 49-54
57. C Franzius, J Sciuk, HE Daldrup-Link, et al. (2000) FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27 1305-1311
58. W Brenner, KH Bohuslavizki and JF Eary (2003) PET imaging of osteosarcoma. J Nucl Med 44 930-942
59. P Picci, D Vanel, A Briccoli, et al. (2001) Computed tomography of pulmonary metastases from osteosarcoma: the less poor technique. A study of 51 patients with histological correlation. Ann Oncol 12 1601-1604
60. D Vanel, M Henry-Amar, J Lumbroso, et al. (1984) Pulmonary evaluation of patients with osteosarcoma: roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy. AJR Am J Roentgenol 143 519-523
61. ML Kayton, AG Huvos, J Casher, et al. (2006) Computed tomographic scan of the chest underestimates the number of metastatic lesions in osteosarcoma. J Pediatr Surg 41 200-206
62. VA White, CV Fanning, AG Ayala, et al. (1988) Osteosarcoma and the role of fine-needle aspiration. A study of 51 cases. Cancer 62 1238-1246
63. JS Jelinek, MD Murphey, JA Welker, et al. (2002) Diagnosis of primary bone tumors with image-guided percutaneous biopsy: experience with 110 tumors. Radiology 223 731-737
64. AG Ayala and J Zornosa (1983) Primary bone tumors: percutaneous needle biopsy. Radiologic-pathologic study of 222 biopsies. Radiology 149 675-679
65. DJ Stoker, JP Cobb and JA Pringle (1991) Needle biopsy of musculoskeletal lesions. A review of 208 procedures. J Bone Joint Surg Br 73 498-500
66. L Yao, SD Nelson, LL Seeger, et al. (1999) Primary musculoskeletal neoplasms: effectiveness of core-needle biopsy. Radiology 212 682-686
67. K Ahrar, JU Himmerich, CE Herzog, et al. (2004) Percutaneous ultrasound-guided biopsy in the definitive diagnosis of osteosarcoma. J Vasc Interv Radiol 15 1329-1333
68. NM Davies, PJ Livesley and SR Cannon (1993) Recurrence of an osteosarcoma in a needle biopsy track. J Bone Joint Surg Br 75 977-978
69. K Iemsawatdikul, CA Gooding, EL Twomey, et al. (2005) Seeding of osteosarcoma in the biopsy tract of a patient with multifocal osteosarcoma. Pediatr Radiol 35 717-721
70. TD Peabody and MA Simon (1996) Making the diagnosis: keys to a successful biopsy in children with bone and soft-tissue tumors. Orthop Clin North Am 27 453-459
71. HJ Mankin, CJ Mankin and MA Simon (1996) The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 78 656-663
72. WP Thorpe, JJ Reilly and SA Rosenberg (1979) Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer 43 2178-2181
73. DC Dahlin and KK Unni (Eds) (1986) Bone Tumors 4th ed Springfield, Ill: Charles C Thomas
74. G Bacci, S Ferrari, N Delepine, et al. (1998) Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 16 658-663
75. CDM Fletcher, KK Unni and F Mertens (Eds) (2002) World Health Organization Classification of Tumours. Pathology and Genetics, Tumours of Soft Tissue and Bone. Lyon, France: IARC Press
76. EI Hauben, S Weeden, J Pringle, et al. (2002) Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38 1218-1225
77. G Bacci, F Bertoni, A Longhi, et al. (2003) Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 97 3068-3075
78. AG Huvos, G Rosen, SS Bretsky and A Butler (1982) Telangiectatic osteogenic sarcoma: a clinicopathologic study of 124 patients. Cancer 49 1679-1689
79. G Bacci, S Ferrari, P Ruggieri, et al. (2001) Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases. Acta Orthop Scand 72 167-172
80. T Matsuno, KK Unni, RA McLeod and DC Dahlin (1976) Telangiectatic osteogenic sarcoma. Cancer 38 2538-2547
81. H Nakajima, FH Sim, JR Bond and KK Unni (1997) Small cell osteosarcoma of bone. Review of 72 cases. Cancer 79 2095-2106
82. AG Ayala, JY Ro, AK Raymond, et al. (1989) Small cell osteosarcoma. A clinicopathologic study of 27 cases. Cancer 64 2162-2173
83. F Bertoni, P Dallera, P Bacchini, et al. (1991) The Istituto Rizzoli-Beretta experience with osteosarcoma of the jaw. Cancer 68 1555-1563
84. JL Clark, KK Unni, DC Dahlin and KD Devine (1983) Osteosarcoma of the jaw. Cancer 51 2311-2316
85. SR Gadwal, FH Gannon, JC Fanburg-Smith, et al. (2001) Primary osteosarcoma of the head and neck in pediatric patients: a clinicopathologic study of 22 cases with a review of the literature. Cancer 91 598-605
86. AM Kurt, KK Unni, RA McLeod and DJ Pritchard (1990) Low-grade intraosseous osteosarcoma. Cancer 65 1418-1428
87. F Bertoni, P Bacchini, N Fabbri, et al. (1993) Osteosarcoma. Low-grade intraosseous-type osteosarcoma, histologically resembling parosteal osteosarcoma, fibrous dysplasia, and desmoplastic fibroma. Cancer 71 338-345
88. K Okada, FJ Frassica, FH Sim, et al. (1994) Parosteal osteosarcoma. A clinicopathological study. J Bone Joint Surg Am 76 366-378
89. F Bertoni, P Bacchini, EL Staals and P Davidovitz (2005) Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer 103 2373-2382
90. M Agarwal, A Puri, C Anchan, et al. (2007) Hemicortical excision for low-grade selected surface sarcomas of bone. Clin Orthop Relat Res 459 161-166
91. KK Unni, DC Dahlin and JW Beabout (1976) Periosteal osteogenic sarcoma. Cancer 37 2476-2485
92. MD Tabone, P Terrier, H Pacquement, et al. (1999) Outcome of radiation-related osteosarcoma after treatment of childhood and adolescent cancer: a study of 23 cases. J Clin Oncol 17 2789-2795
93. M Shaheen, BM Deheshi, S Riad, et al. (2006) Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma. Clin Orthop Relat Res 450 76-81
94. WF Enneking, SS Spanier and MA Goodman (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 153 106-120
95. AC Broders (1941) The microscopic grading of cancer. Surg Clin North Am 21 947-962
96. WF Enneking, SS Spanier and MA Goodman (1980) Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 62 1027-1030
97. RE Wolf and WF Enneking (1996) The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am 27 473-481
98. HJ Mankin, FJ Hornicek, AE Rosenberg, et al. (2004) Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 429 286-291
99. DC Dahlin and MB Coventry (1967) Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am 49 101-110
100. N Jaffe, E Frei III, D Traggis and Y Bishop (1974) Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 291 994-997
101. PA Meyers, CL Schwartz, M Krailo, et al. (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23 2004-2011
102. AM Goorin, DJ Schwartzentruber, M Devidas, et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21 1574-1580
103. PA Meyers, R Gorlick, G Heller, et al. (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16 2452-2458
104. S Ferrari, S Smeland, M Mercuri, et al. (2005) Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23 8845-8852
105. DS Hawkins and CA Arndt (2003) Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98 2447-2456
106. G Bacci, S Ferrari, F Bertoni, et al. (2000) Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18 4016-4027
107. DB Glasser, JM Lane, AG Huvos, et al. (1992) Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 69 698-708
108. M Eselgrim, H Grunert, T Kuhne, et al. (2006) Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer 47 42-50
109. G Bacci, P Picci, P Ruggieri, et al. (1990) Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65 2539-2553
110. PA Meyers, G Heller, J Healey, et al. (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10 5-15
111. P Bieling, N Rehan, P Winkler, et al. (1996) Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 14 848-858
112. AM Davis, RS Bell and PJ Goodwin (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12 423-431
113. G Rosen, ML Murphy, AG Huvos, et al. (1976) Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37 1-11
114. G Rosen, RC Marcove, B Caparros, et al. (1979) Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43 2163-2177
115. K Winkler, G Beron, R Kotz, et al. (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 2 617-624
116. K Winkler, G Beron, G Delling, et al. (1988) Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 6 329-337
117. VH Bramwell, M Burgers, R Sneath, et al. (1992) A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 10 1579-1591
118. M Krailo, I Ertel, J Makley, et al. (1987) A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. Med Pediatr Oncol 15 69-77
119. AM Goorin, A Perez-Atayde, M Gebhardt, et al. (1987) Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital—study III. J Clin Oncol 5 1178-1184
120. AJ Provisor, LJ Ettinger, JB Nachman, et al. (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 15 76-84
121. N Fuchs, SS Bielack, D Epler, et al. (1998) Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 9 893-899
122. JH Edmonson, SJ Green, JC Ivins, et al. (1984) A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 2 152-156
123. WF Taylor, JC Ivins, KK Unni, et al. (1989) Prognostic variables in osteosarcoma: a multi-institutional study. J Natl Cancer Inst 81 21-30
124. M Hudson, MR Jaffe, N Jaffe, et al. (1990) Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 8 1988-1997
125. C Khanna, X Wan, S Bose, et al. (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10 182-186
126. R Gorlick, AG Huvos, G Heller, et al. (1999) Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17 2781-2788
127. O Feugeas, N Guriec, A Babin-Boilletot, et al. (1996) Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14 467-472
128. G Bacci, A Longhi, M Cesari, et al. (2006) Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. Cancer 106 2701-2706
129. V Mialou, T Philip, C Kalifa, et al. (2005) Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome—the French pediatric experience. Cancer 104 1100-1109
130. AM Goorin, MB Harris, M Bernstein, et al. (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20 426-433
131. JA Bridge, M Nelson, E McComb, et al. (1997) Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 95 74-87
132. JA Fletcher, MC Gebhardt and HP Kozakewich (1994) Cytogenetic aberrations in osteosarcomas. Nonrandom deletions, rings, and double-minute chromosomes. Cancer Genet Cytogenet 77 81-88
133. AA Sandberg and JA Bridge (2003) Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 145 1-30
134. J Bayani, M Zielenska, A Pandita, et al. (2003) Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 36 7-16
135. M Tarkkanen, I Elomaa, C Blomqvist, et al. (1999) DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer 84 114-121
136. T Ozaki, KL Schaefer, D Wai, et al. (2002) Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. Int J Cancer 102 355-365
137. CC Lau, CP Harris, XY Lu, et al. (2004) Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39 11-21
138. M Zielenska, J Bayani, A Pandita, et al. (2001) Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma. Cancer Genet Cytogenet 130 14-21
139. C Stock, L Kager, FM Fink, et al. (2000) Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 28 329-336
140. D Gisselsson, E Palsson, M Hoglund, et al. (2002) Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer 33 133-140
141. M van Dartel, PW Cornelissen, S Redeker, et al. (2002) Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. Cancer Genet Cytogenet 139 91-96
142. TK Man, XY Lu, K Jaeweon, et al. (2004) Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4 45
143. F Pompetti, P Rizzo, RM Simon, et al. (1996) Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63 37-50
144. M Ladanyi, CK Park, R Lewis, et al. (1993) Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2 163-167
145. G Gamberi, MS Benassi, T Bohling, et al. (1998) C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55 556-563
146. JH Patel, AP Loboda, MK Showe, et al. (2004) Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 4 562-568
147. S Pelengaris, M Khan and G Evan (2002) c-MYC: more than just a matter of life and death. Nat Rev Cancer 2 764-776
148. TW Corson and BL Gallie (2007) One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 46 617-634
149. S Richter, K Vandezande, N Chen, et al. (2003) Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 72 253-269
150. GJ Draper, BM Sanders and JE Kingston (1986) Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53 661-671
151. WK Cavenee, MF Hansen, M Nordenskjold, et al. (1985) Genetic origin of mutations predisposing to retinoblastoma. Science 228 501-503
152. WK Cavenee, TP Dryja, RA Phillips, et al. (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305 779-784
153. J Toguchida, K Ishizaki, MS Sasaki, et al. (1988) Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res 48 3939-3943
154. JS Wunder, AA Czitrom, R Kandel and IL Andrulis (1991) Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst 83 194-200
155. SH Friend, JM Horowitz, MR Gerber, et al. (1987) Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A 84 9059-9063
156. J Toguchida, K Ishizaki, MS Sasaki, et al. (1989) Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 338 156-158
157. MS Benassi, L Molendini, G Gamberi, et al. (1999) Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer 84 489-493
158. S Heinsohn, U Evermann, SU Zur, et al. (2007) Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. Int J Oncol 30 1205-1214
159. W Li, J Fan, D Hochhauser, et al. (1995) Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci U S A 92 10436-10440
160. M Classon and E Harlow (2002) The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2 910-917
161. L Khidr and PL Chen (2006) Rb, the conductor that orchestrates life, death and differentiation. Oncogene 25 5210-5219
162. DX Nguyen and DJ McCance (2005) Role of the retinoblastoma tumor suppressor protein in cellular differentiation. J Cell Biochem 94 870-879
163. L Wu, BA de, HI Saavedra, et al. (2003) Extra-embryonic function of Rb is essential for embryonic development and viability. Nature 421 942-947
164. DM Thomas, SA Carty, DM Piscopo, et al. (2001) The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 8 303-316
165. D Malkin, KW Jolly, N Barbier, et al. (1992) Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326 1309-1315
166. JM Varley (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21 313-320
167. D Malkin, FP Li, LC Strong, et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 1233-1238
168. CW Miller, A Aslo, A Won, et al. (1996) Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 122 559-565
169. CW Miller, A Aslo, C Tsay, et al. (1990) Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50 7950-7954
170. H Masuda, C Miller, HP Koeffler, et al. (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A 84 7716-7719
171. J Toguchida, T Yamaguchi, B Ritchie, et al. (1992) Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52 6194-6199
172. N Gokgoz, JS Wunder, S Mousses, et al. (2001) Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 92 2181-2189
173. A Patino-Garcia and L Sierrasesumaga (1997) Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet Cytogenet 98 50-55
174. T Tsuchiya, K Sekine, S Hinohara, et al. (2000) Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120 91-98
175. F Lonardo, T Ueda, AG Huvos, et al. (1997) p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 79 1541-1547
176. JF McIntyre, B Smith-Sorensen, SH Friend, et al. (1994) Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 12 925-930
177. J Toguchida, T Yamaguchi, SH Dayton, et al. (1992) Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 326 1301-1308
178. A Petitjean, MI Achatz, AL Borresen-Dale, et al. (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 2157-2165
179. AJ Levine (1997) p53, the cellular gatekeeper for growth and division. Cell 88 323-331
180. CR Walkley, R Qudsi, VG Sankaran, et al. (2008) Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 22 1662-1676
181. SD Berman, E Calo, AS Landman, et al. (2008) Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. PNAS 105 1851-1856
182. LA Donehower, M Harvey, BL Slagle, et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 215-221
183. T Jacks, L Remington, BO Williams, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4 1-7
184. KP Olive, DA Tuveson, ZC Ruhe, et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119 847-860
185. G Liu, TJ McDonnell, LR Montes de Oca, et al. (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A 97 4174-4179
186. A Lavigueur, V Maltby, D Mock, et al. (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9 3982-3991
187. BB Knowles, J McCarrick, N Fox, et al. (1990) Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am J Pathol 137 259-262
188. TM Wilkie, RA Schmidt, M Baetscher and A Messing (1994) Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen. Oncogene 9 2889-2895
189. RI Aqeilan, F Trapasso, S Hussain, et al. (2007) Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci U S A 104 3949-3954
190. M Jain, C Arvanitis, K Chu, et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297 102-104
191. JS Wunder, N Gokgoz, R Parkes, et al. (2005) TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 23 1483-1490
192. EE Pakos, PA Kyzas and JP Ioannidis (2004) Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res 10 6208-6214
193. B Vogelstein, D Lane and AJ Levine (2000) Surfing the p53 network. Nature 408 307-310
194. Y Haupt, R Maya, A Kazaz and M Oren (1997) Mdm2 promotes the rapid degradation of p53. Nature 387 296-299
195. MH Kubbutat, SN Jones and KH Vousden (1997) Regulation of p53 stability by Mdm2. Nature 387 299-303
196. SY Fuchs, V Adler, T Buschmann, et al. (1998) Mdm2 association with p53 targets its ubiquitination. Oncogene 17 2543-2547
197. D arcon-Vargas and Z Ronai (2002) p53-Mdm2—the affair that never ends. Carcinogenesis 23 541-547
198. JD Oliner, KW Kinzler, PS Meltzer, et al. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 80-83
199. M Ladanyi, C Cha, R Lewis, et al. (1993) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53 16-18
200. J Momand, D Jung, S Wilczynski and J Niland (1998) The MDM2 gene amplification database. Nucleic Acids Res 26 3453-3459
201. JS Wunder, K Eppert, SR Burrow, et al. (1999) Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 18 783-788
202. P Ragazzini, G Gamberi, MS Benassi, et al. (1999) Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma. Cancer Detect Prev 23 129-136
203. D Bech-Otschir, R Kraft, X Huang, et al. (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20 1630-1639
204. J Henriksen, TH Aagesen, GM Maelandsmo, et al. (2003) Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 22 5358-5361
205. T Yan, JS Wunder, N Gokgoz, et al. (2007) COPS3 amplification and clinical outcome in osteosarcoma. Cancer 109 1870-1876
206. GP Nielsen, KL Burns, AE Rosenberg and DN Louis (1998) CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 153 159-163
207. A Maitra, H Roberts, AG Weinberg and J Geradts (2001) Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. Int J Cancer 95 34-38
208. YB Park, MJ Park, K Kimura, et al. (2002) Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 133 105-111
209. CJ Sherr (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6 663-673
210. K Nishijo, T Nakayama, T Aoyama, et al. (2004) Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer 111 367-372
211. S Kitao, A Shimamoto, M Goto, et al. (1999) Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet 22 82-84
212. LL Wang, ML Levy, RA Lewis, et al. (2001) Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 102 11-17
213. NA Ellis, J Groden, TZ Ye, et al. (1995) The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83 655-666
214. CE Yu, J Oshima, YH Fu, et al. (1996) Positional cloning of the Werner's syndrome gene. Science 272 258-262
215. MB Mann, CA Hodges, E Barnes, et al. (2005) Defective sister-chromatid cohesion, aneuploidy and cancer predisposition in a mouse model of type II Rothmund-Thomson syndrome. Hum Mol Genet 14 813-825
216. ID Hickson (2003) RecQ helicases: caretakers of the genome. Nat Rev Cancer 3 169-178
217. MN Sangrithi, JA Bernal, M Madine, et al. (2005) Initiation of DNA replication requires the RECQL4 protein mutated in Rothmund-Thomson syndrome. Cell 121 887-898
218. MS Eller, X Liao, S Liu, et al. (2006) A role for WRN in telomere-based DNA damage responses. Proc Natl Acad Sci U S A 103 15073-15078
219. JS Rhim, DK Park, P Arnstein, et al. (1975) Transformation of human cells in culture by N-methyl-N′-nitro-N-nitrosoguanidine. Nature 256 751-753
220. CS Cooper, M Park, DG Blair, et al. (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311 29-33
221. M Park, M Dean, CS Cooper, et al. (1986) Mechanism of met oncogene activation. Cell 45 895-904
222. K Scotlandi, N Baldini, M Oliviero, et al. (1996) Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 149 1209-1219
223. R Ferracini, MF Di Renzo, K Scotlandi, et al. (1995) The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10 739-749
224. Y Oda, T Naka, M Takeshita, et al. (2000) Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol 31 709-716
225. V Wallenius, M Hisaoka, K Helou, et al. (2000) Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am J Pathol 156 821-829
226. S Patane, S Avnet, N Coltella, et al. (2006) MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 66 4750-4757
227. R Ferracini, P Angelini, E Cagliero, et al. (2000) MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 18 253-256
228. EG MacEwen, J Kutzke, J Carew, et al. (2003) c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 20 421-430
229. N Coltella, MC Manara, V Cerisano, et al. (2003) Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 17 1162-1164
230. L Trusolino and PM Comoglio (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2 289-300
231. MP Finkel, BO Biskis and PB Jinkins (1966) Virus induction of osteosarcomas in mice. Science 151 698-701
232. C Van Beveren, F van Straaten, T Curran, et al. (1983) Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell 32 1241-1255
233. AD Miller, T Curran and IM Verma (1984) c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell 36 51-60
234. AE Grigoriadis, K Schellander, ZQ Wang and EF Wagner (1993) Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 122 685-701
235. U Ruther, D Komitowski, FR Schubert and EF Wagner (1989) c-fos expression induces bone tumors in transgenic mice. Oncogene 4 861-865
236. JX Wu, PM Carpenter, C Gresens, et al. (1990) The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5 989-1000
237. A Franchi, A Calzolari and G Zampi (1998) Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch 432 515-519
238. A Sunters, DP Thomas, WA Yeudall and AE Grigoriadis (2004) Accelerated cell cycle progression in osteoblasts overexpressing the c-fos proto-oncogene: induction of cyclin A and enhanced CDK2 activity. J Biol Chem 279 9882-9891
239. EF Wagner (2002) Functions of AP1 (Fos/Jun) in bone development. Ann Rheum Dis 61(suppl 2), ii40-ii42
240. RS Johnson, BM Spiegelman and V Papaioannou (1992) Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71 577-586
241. ZQ Wang, C Ovitt, AE Grigoriadis, et al. (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360 741-745
242. RA Tjalma (1966) Canine bone sarcoma: estimation of relative risk as a function of body size. J Natl Cancer Inst 36 1137-1150
243. O Larsson, A Girnita and L Girnita (2005) Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92 2097-2101
244. NB Sutter, CD Bustamante, K Chase, et al. (2007) A single IGF1 allele is a major determinant of small size in dogs. Science 316 112-115
245. JP Liu, J Baker, AS Perkins, et al. (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75 59-72
246. MJ Abuzzahab, A Schneider, A Goddard, et al. (2003) IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 349 2211-2222
247. Y Kawashima, S Kanzaki, F Yang, et al. (2005) Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 90 4679-4687
248. MN Pollak, C Polychronakos and M Richard (1990) Insulin like growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82 301-305
249. K Scotlandi, MC Manara, G Nicoletti, et al. (2005) Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65 3868-3876
250. R Braczkowski, AV Schally, A Plonowski, et al. (2002) Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 95 1735-1745
251. CC Kappel, MC Velez-Yanguas, S Hirschfeld and LJ Helman (1994) Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 54 2803-2807
252. K Raile, A Hoflich, U Kessler, et al. (1994) Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J Cell Physiol 159 531-541
253. R Rosato, K Gerland, H Jammes, et al. (2001) The IGFBP-3 mRNA and protein levels are IGF-I-dependent and GH-independent in MG-63 human osteosarcoma cells. Mol Cell Endocrinol 175 15-27
254. M Pasello, CM Hattinger, G Stoico, et al. (2005) 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. Eur J Cancer 41 2184-2195
255. EK Maloney, JL McLaughlin, NE Dagdigian, et al. (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63 5073-5083
256. MC Velez-Yanguas, T Kalebic, M Maggi, et al. (1996) 1-alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J Clin Endocrinol Metab 81 93-99
257. MR Schneider, R Zhou, A Hoeflich, et al. (2001) Insulin-like growth factor-binding protein-5 inhibits growth and induces differentiation of mouse osteosarcoma cells. Biochem Biophys Res Commun 288 435-442
258. M Pollak, AW Sem, M Richard, et al. (1992) Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84 966-971
259. C Rodriguez-Galindo, CA Poquette, NC Daw, et al. (2001) Circulating concentrations of IGF-I and IGFBP-3 are not predictive of incidence or clinical behavior of pediatric osteosarcoma. Med Pediatr Oncol 36 605-611
260. R Seshadri, FA Firgaira, DJ Horsfall, et al. (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11 1936-1942
261. HB Muss, AD Thor, DA Berry, et al. (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330 1260-1266
262. DJ Slamon, B Leyland-Jones, S Shak, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 783-792
263. M Onda, S Matsuda, S Higaki, et al. (1996) ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77 71-78
264. H Zhou, RL Randall, AR Brothman, et al. (2003) Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25 27-32
265. GR Somers, M Ho, M Zielenska, et al. (2005) HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol 8 525-532
266. A Maitra, D Wanzer, AG Weinberg and R Ashfaq (2001) Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92 677-683
267. T Akatsuka, T Wada, Y Kokai, et al. (2002) ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94 1397-1404
268. Ebb D, Meyers P, Devidas M. Study Committee Progress Report AOST0121. Children's Oncology Group 10-1-2007
269. CC Bleul, RC Fuhlbrigge, JM Casasnovas, et al. (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184 1101-1109
270. SK Gupta, PG Lysko, K Pillarisetti, et al. (1998) Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem 273 4282-4287
271. RS Taichman, C Cooper, ET Keller, et al. (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62 1832-1837
272. J Libura, J Drukala, M Majka, et al. (2002) CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 100 2597-2606
273. A Corcione, L Ottonello, G Tortolina, et al. (2000) Stromal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. J Natl Cancer Inst 92 628-635
274. C Laverdiere and R Gorlick (2006) CXCR4 expression in osteosarcoma cell lines and tumor samples: evidence for expression by tumor cells. Clin Cancer Res 12 5254
275. C Laverdiere, BH Hoang, R Yang, et al. (2005) Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 11 2561-2567
276. E Perissinotto, G Cavalloni, F Leone, et al. (2005) Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 11 490-497
277. C Khanna, J Khan, P Nguyen, et al. (2001) Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61 3750-3759
278. C Khanna, J Prehn, C Yeung, et al. (2000) An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 18 261-271
279. S Rong, M Jeffers, JH Resau, et al. (1993) Met expression and sarcoma tumorigenicity. Cancer Res 53 5355-5360
280. P Mehlen and A Puisieux (2006) Metastasis: a question of life or death. Nat Rev Cancer 6 449-458
281. EA Lafleur, SF Jia, LL Worth, et al. (2001) Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 61 4066-4071
282. EA Lafleur, NV Koshkina, J Stewart, et al. (2004) Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 10 8114-8119
283. X Duan, SF Jia, N Koshkina and ES Kleinerman (2006) Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 106 1382-1388
284. SF Jia, LL Worth, CL Densmore, et al. (2003) Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res 9 3462-3468
285. SF Jia, LL Worth, CL Densmore, et al. (2002) Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther 9 260-266
286. LL Worth, SF Jia, Z Zhou, et al. (2000) Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res 6 3713-3718
287. N Gordon, CA Arndt, DS Hawkins, et al. (2005) Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27 611-615
288. HJ Cho, TS Lee, JB Park, et al. (2007) Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40 1069-1076
289. N Baldini, K Scotlandi, G Barbanti-Brodano, et al. (1995) Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333 1380-1385
290. M Serra, K Scotlandi, G Reverter-Branchat, et al. (2003) Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 21 536-542
291. HS Chan, TM Grogan, G Haddad, et al. (1997) P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89 1706-1715
292. FJ Hornicek, MC Gebhardt, MW Wolfe, et al. (2000) P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop Relat Res 373 11-17
293. YB Park, HS Kim, JH Oh and SH Lee (2001) The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24 307-310
294. O Yamamoto, T Wada, M Takahashi, et al. (2000) Prognostic value of P-glycoprotein expression in bone and soft-tissue sarcoma. Int J Clin Oncol 5 164-170
295. EE Pakos and JP Ioannidis (2003) The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer 98 581-589
296. CL Schwartz, R Gorlick, L Teot, et al. (2007) Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol 25 2057-2062
297. JS Wunder, RS Bell, L Wold and IL Andrulis (1993) Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Orthop Res 11 396-403
298. JS Wunder, SB Bull, V Aneliunas, et al. (2000) MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18 2685-2694
299. PA Meyers and R Gorlick (1997) Osteosarcoma. Pediatr Clin North Am 44 973-989
300. W Guo, JH Healey, PA Meyers, et al. (1999) Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 5 621-627
301. K Ochi, Y Daigo, T Katagiri, et al. (2004) Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 24 647-655
302. MB Mintz, R Sowers, KM Brown, et al. (2005) An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65 1748-1754
303. TK Man, M Chintagumpala, J Visvanathan, et al. (2005) Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65 8142-8150
304. N Jaffe, H Carrasco, K Raymond, et al. (2002) Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer 95 2202-2210
305. RJ Grimer, AM Taminiau and SR Cannon (2002) Surgical outcomes in osteosarcoma. J Bone Joint Surg Br 84 395-400
306. P Picci, L Sangiorgi, BT Rougraff, et al. (1994) Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 12 2699-2705
307. RJ Grimer (2005) Surgical options for children with osteosarcoma. Lancet Oncol 6 85-92
308. EP Cortes, JF Holland, JJ Wang, et al. (1974) Amputation and adriamycin in primary osteosarcoma. N Engl J Med 291 998-1000
309. LJ Ettinger, HO Douglass Jr, DJ Higby, et al. (1981) Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma. Cancer 47 248-254
310. WW Sutow, MP Sullivan, DJ Fernbach, et al. (1975) Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study. Cancer 36 1598-1602
311. B Lange, S Kramer, JR Gregg, et al. (1982) High-dose methotrexate and adriamycin in osteogenic sarcoma: the children's hospital of Philadelphia study. Am J Clin Oncol 5 3-8
312. WF Taylor, JC Ivins, DC Dahlin, et al. (1978) Trends and variability in survival from osteosarcoma. Mayo Clin Proc 53 695-700
313. B Lange and AS Levine (1982) Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma? Cancer Treat Rep 66 1699-1704
314. MP Link, AM Goorin, AW Miser, et al. (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314 1600-1606
315. F Eilber, A Giuliano, J Eckardt, et al. (1987) Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5 21-26
316. JJ Ochs, AI Freeman, HO Douglass Jr, et al. (1978) cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62 239-245
317. S Ferrari, M Mercuri, P Picci, et al. (1999) Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 85 458-464
318. RM Wilkins, JW Cullen, L Odom, et al. (2003) Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 10 498-507
319. WS Ferguson, MB Harris, AM Goorin, et al. (2001) Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol 23 340-348
320. MC Le Deley, JM Guinebretiere, JC Gentet, et al. (2007) SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43 752-761
321. CB Pratt, ME Horowitz, WH Meyer, et al. (1987) Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 71 131-135
322. S Smeland, C Muller, TA Alvegard, et al. (2003) Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39 488-494
323. WH Meyer, CB Pratt, CA Poquette, et al. (2001) Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 19 171-182
324. YM Wang, WW Sutow, MM Romsdahl and C Perez (1979) Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. Cancer Treat Rep 63 405-410
325. N Graf, K Winkler, M Betlemovic, et al. (1994) Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 12 1443-1451
326. KR Crews, T Liu, C Rodriguez-Galindo, et al. (2004) High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100 1724-1733
327. N Jaffe, J Prudich, J Knapp, et al. (1983) Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate. J Clin Oncol 1 428-431
328. G Rosen, B Caparros, AG Huvos, et al. (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49 1221-1230
329. CB Pratt, S Epelman and N Jaffe (1987) Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients. Cancer Treat Rep 71 421-423
330. H Strander and S Einhorn (1977) Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer 19 468-473
331. S Masuda, H Fukuma and Y Beppu (1983) Antitumor effect of human leukocyte interferon on human osteosarcoma transplanted into nude mice. Eur J Cancer Clin Oncol 19 1521-1528
332. H Strander, HC Bauer, O Brosjo, et al. (1995) Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 34 877-880
333. IJ Fidler, S Sone, WE Fogler and ZL Barnes (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A 78 1680-1684
334. EG MacEwen, ID Kurzman, RC Rosenthal, et al. (1989) Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81 935-938
335. RL Souhami, AW Craft, JW Van der Eijken, et al. (1997) Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350 911-917
336. IJ Lewis, MA Nooij, J Whelan, et al. (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99 112-128
337. A Goorin, A Cantor and MP Link (1994) A phase I trial of etoposide and escalating doses of ifosfamide in recurrent pediatric sarcomas. Proc Am Soc Clin Oncol 13 A1458
338. RJ Pietras, BM Fendly, VR Chazin, et al. (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 1829-1838
339. CL Arteaga, AR Winnier, MC Poirier, et al. (1994) p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 54 3758-3765
340. MC Hancock, BC Langton, T Chan, et al. (1991) A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51 4575-4580
341. J Baselga, L Norton, J Albanell, et al. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58 2825-2831
342. E Aboud-Pirak, E Hurwitz, ME Pirak, et al. (1988) Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80 1605-1611
343. CA Hudis (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357 39-51
344. E Corey, LG Brown, JE Quinn, et al. (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9 295-306
345. A Evdokiou, A Labrinidis, S Bouralexis, et al. (2003) Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 33 216-228
346. T Iguchi, Y Miyakawa, K Saito, et al. (2007) Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 31 285-291
347. B Ory, MF Heymann, A Kamijo, et al. (2005) Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104 2522-2529
348. D Heymann, B Ory, F Blanchard, et al. (2005) Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37 74-86
349. DG Little, NC Smith, PR Williams, et al. (2003) Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res 18 1300-1307
350. JD Bobyn, SA Hacking, JJ Krygier, et al. (2005) Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg Br 87 416-420
351. F Duffaud, L Digue, C Mercier, et al. (2003) Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer 39 2050-2057
352. G Saeter, J Hoie, AE Stenwig, et al. (1995) Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long-term survival. Cancer 75 1084-1093
353. A Briccoli, M Rocca, M Salone, et al. (2005) Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 104 1721-1725
354. M Antunes, J Bernardo, M Salete, et al. (1999) Excision of pulmonary metastases of osteogenic sarcoma of the limbs. Eur J Cardiothorac Surg 15 592-596
355. MT Harting, ML Blakely, N Jaffe, et al. (2006) Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 41 194-199
356. J Pfannschmidt, J Klode, T Muley, et al. (2006) Pulmonary resection for metastatic osteosarcomas: a retrospective analysis of 21 patients. Thorac Cardiovasc Surg 54 120-123
357. AM Goorin, MJ Delorey, EE Lack, et al. (1984) Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 2 425-431
358. SS Nathan, R Gorlick, S Bukata, et al. (2006) Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer 107 1607-1616
359. SF Jia, LL Worth and ES Kleinerman (1999) A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 17 501-506
360. LL Worth, EA Lafleur, SF Jia and ES Kleinerman (2002) Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9 823-827
361. N Gordon, NV Koshkina, SF Jia, et al. (2007) Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13 4503-4510
362. RD Rao, PM Anderson, CA Arndt, et al. (2003) Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol 26 493-498
363. S Joyama, N Naka, Y Tsukamoto, et al. (2006) Dendritic cell immunotherapy is effective for lung metastasis from murine osteosarcoma. Clin Orthop Relat Res 453 318-327
364. MS Merchant, F Melchionda, M Sinha, et al. (2007) Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol Immunother 56 1037-1046
365. X Wan, A Mendoza, C Khanna and LJ Helman (2005) Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65 2406-2411
366. ET Ek, CR Dass, KG Contreras and PF Choong (2007) Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis 24 93-106
367. ET Ek, CR Dass, KG Contreras and PF Choong (2007) PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res
368. N Bodmer, DK Walters and B Fuchs (2007) Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines. Pediatr Blood Cancer
369. R Weichselbaum, JB Little and J Nove (1977) Response of human osteosarcoma in vitro to irradiation: evidence for unusual cellular repair activity. Int J Radiat Biol Relat Stud Phys Chem Med 31 295-299
370. JM Burgers, M van Glabbeke, A Busson, et al. (1988) Osteosarcoma of the limbs. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer 61 1024-1031
371. GN Machak, SI Tkachev, YN Solovyev, et al. (2003) Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 78 147-155
372. T Ozaki, S Flege, U Liljenqvist, et al. (2002) Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer 94 1069-1077
373. EB Hug, MM Fitzek, NJ Liebsch and JE Munzenrider (1995) Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning. Int J Radiat Oncol Biol Phys 31 467-476
374. FO Dincbas, S Koca, NM Mandel, et al. (2005) The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery. Int J Radiat Oncol Biol Phys 62 820-828
375. TF DeLaney, L Park, SI Goldberg, et al. (2005) Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 61 492-498
376. PM Anderson, GA Wiseman, A Dispenzieri, et al. (2002) High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20 189-196
377. S Buchen, D Ngampolo, RG Melton, et al. (2005) Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 92 480-487
378. R Nagarajan, JP Neglia, DR Clohisy and LL Robison (2002) Limb salvage and amputation in survivors of pediatric lower-extremity bone tumors: what are the long-term implications? J Clin Oncol 20 4493-4501
379. SE Lipshultz, SR Lipsitz, SM Mone, et al. (1995) Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332 1738-1743
380. JS Meyer, HR Nadel, N Marina, et al. (2008) Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 51 163-170
381. LT Dauer, J St. Germain and PA Meyers (2008) Let's image gently: reducing excessive reliance on CT scans. Pediatr Blood Cancer 51 838
382. JS Meyer, HR Nadel, N Marina, et al. (2008) Response to “Imaging guidelines for children with Ewing sarcoma and osteosarcoma. A report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 51 839-840. ”
383. LH Wexler, MP Andrich, D Venzon, et al. (1996) Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14 362-372
384. CK Tebbi, WB London, D Friedman, et al. (2007) Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25 493-500
385. G Bacci, C Ferrari, A Longhi, et al. (2006) Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol 28 774-780
386. L Aung, RG Gorlick, W Shi, et al. (2002) Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer 95 1728-1734
387. W Stohr, T Langer, A Kremers, et al. (2005) Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 23 201-207
388. AS Petrilli, DT Oliveira, VC Ginani, et al. (2002) Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol 24 188-191
389. A Longhi, M Macchiagodena, G Vitali and G Bacci (2003) Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol 25 292-296
390. A Longhi, E Pignotti, M Versari, et al. (2003) Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep 10 151-155
391. JT Torbert, EJ Fox, HS Hosalkar, et al. (2005) Endoprosthetic reconstructions: results of long-term followup of 139 patients. Clin Orthop Relat Res 438 51-59